利福昔明治疗轻微型肝性脑病的疗效观察

目的:观察利福昔明治疗轻微型肝性脑病的临床疗效。方法:选取我科室收治的60例轻微型肝性脑病患者作为研究对象,将其按照不同的治疗方法平均分成对照组与观察组各30例,对照组给予乳果糖治疗,观察组给予利福昔明治疗,对比观察两组患者治疗后的临床疗效。结果:对比两组患者治疗后的NCT-A型下降时间、血氨浓度,观察组明显优于对照组,差异显著,有统计学意义(P<0.05);治疗后,观察组的总有效率为93.3%,对照组的总有效率为90.0%,对比两组差异不显著,无统计学意义(P>0.05);观察组的不良反应发生率为10.0%,对照组的不良反应发生率为23.3%,对比两组差异显著,有统计学意义(P<0.05)。结论:利福昔明治疗轻微型肝性脑病的临床疗效与乳果糖治疗相近,但其不良反应发生率较低,值得推广与应用。

Objective: Objective: To observe the clinical efficacy of rifaximin in the treatment of minimal hepatic encephalopathy. Methods: selected in our hospital 60 patients with minimal hepatic encephalopathy patients as the research object, the according to the different treatment methods are divided into control group and observation group, 30 cases in each group, the lactulose treatment was given to the control group, the observation group given rifaximin therapy, observation of the two groups of patients after treatment clinical curative effect. Results: compared with two groups of patients after the nct-a type down time, blood ammonia concentration, the observation group was significantly better than the control group, significant difference, was statistically significant(P < 0.05). After treatment, the observation group, the total efficiency was 93.3%. In the control group the total efficiency was 90.0%, were compared between the two groups were not significant difference, had no statistical significance(P > 0.05); adverse reactions in the observation group occurred rate was 10.0%, control group of adverse reaction rate was 23.3%, compared two groups had significant difference, was statistically significant(P < 0.05). Conclusion: rifaximin in the treatment of mild hepatic encephalopathy of clinical curative effect of treatment with lactulose is similar, but the incidence rate of adverse reaction is lower, it is worth popularization and application.